Assessing glycemia in type 1 diabetic patients using a microdialysis system for continuous glucose monitoring

Annals of Saudi Medicine

Volumn 27, Issue 3, 2007, Pages 166-170

  Radman, Maja ^a   Jurišić, Dubravka ^b   Ljutić, Dragan ^a   Jerković, Romana ^c   Kovačić, Nataša ^d   Hozo, Izet Salih ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b KBC RIJEKA   (Croatia)

^c UNIVERSITY OF RIJEKA   (Croatia)

^d University of Rijeka ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC KIT; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICRODIALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REFERENCE VALUE; SELF MONITORING; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

EID: 34447328989     PISSN: 02564947     EISSN: 13199226     Source Type: Journal    
DOI: 10.5144/0256-4947.2007.166     Document Type: Article

References (30)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Metelko Ž, Renar IP, Poljcanin T, et al. The first national diabetes prevalence survey in Croatia - unexpected high prevalence. Diabetes 2004;53 (suppl.2): A250.
3. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. Valeri C, Pozzilli P, Leslie D. Glucose control in diabetes. Diabetes Metab Res Rev 2004; 20(suppl 2): S1-S8.
5. DCCT Research Group. The absence of a glycemic threshold for the development of long term complications: the perspective of the diabetes control and complication trial. Diabetes 1996; 45: 1289-1298.
6. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated haemoglobin: a pilot study. Diab Res Clin Pract 1999; 46: 183-190.
7. Klonoff DC. Continuous glucose monitoring. Diabetes Care 2005;28: 1231-1239.
8. Saudek CD, Derr RL, Kalyani RR. Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A1c. JAMA 2006; 295: 1688-1697.
9. Bolli GB. Rational use of insulin analogues in the treatment of type 1 diabetes mellitus. Pediatric Endocrinol Rev 2003; 1: 9-21.
10. Ratner RE, Hirsh IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes: U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-643.
11. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
12. Rosenstock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in type 2 diabetes. Diabetes Care 2001;24: 631-636.
13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
15. Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23: 1137-1142.
16. Maran A, Crepaldi C, Tiengo A, et al. Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care 2002; 25: 347-352.
17. Ritzel RA, Veldhuis JD, Butler PC. Glucose stimulates pulsatile insulin secretion from human pancreatic islets by increasing secretory burst mass: dose-response relationships. J Clin Endocrinol Metab 2003; 88: 742-747.
18. Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. Diabetes Metab Res Rev 2004; 20(Suppl 2): S32-S42.
19. National Institute for clinical excellence. Final appraisal determination. Long acting insulin analogues for the treatment of diabetes-insulin glargine. October 2002, www.nice.org.uk/glargine.
20. Schiaffini R, Ciampalini P, Spera S, et al. An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. Diabetes Metab Res Rev 2004; 21: 347-52.
21. Kudva YC, Basu A, Jenkins GD, et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005; 28: 10-14.
22. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000; 23: 157-162.
23. Service FJ, O'Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care 1987;10: 225-237.
24. Levin P, Soumai M, Mersey J. Improvement of brittle diabetes control after switching to insulin glargine (Lantus) from NPH insulin: a continuous glucose monitoring study. Diabetes Metabolism 2003; 29: A 2218.
25. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
26. Gerich J, Bolli G, Becker R, et al. Fluctuations of serum insulin levels after single and multiple dosing of insulin glargine. Diabetologia 2003; 46: A783.
27. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
28. Porcellati F, Pampanelli S, Fanelli C, et al. Comparison between different regimens of basal insulin supplementation in the prevention of nocturnal hypoglycemia in intensive treatment of type 1 diabetes. Diabetologia 2001; 44: A 799.
29. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003; 26: 1490-6.
30. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21:1213-20.